Diovan reduces cardiovascular events by 45 percent

Thursday, September 3rd, 2009

Data presented yesterday at the European Society of Cardiology (ESC) Congress in Barcelona, Spain, demonstrated that the addition of the angiotensin receptor blocker (ARB) Diovan (valsartan) to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative reduction in cardiovascular events.   A total of 3,042 Japanese patients with high blood pressure […]